Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Bank of New York Mellon Corp (BNY) vs CVS Health Corp (CVS) Price & Performance

Bank of New York Mellon CorpTrade
CVS Health CorpTrade

Price performance (Past 24H)

Key statistics

Bank of New York Mellon Corp vs CVS Health Corp — how do they compare? Bank of New York Mellon Corp trades at $154.01 (market cap $106.05B), while CVS Health Corp trades at $105.81 (market cap $135.48B). The key difference: CVS Health Corp is the larger of the two by market cap, and CVS Health Corp pays the higher dividend (2.51%). Which is the better fit depends on your goals.

BNYCVS
Market Cap
$106.05B$135.48B
Sector
FinancialsHealth
52-Week High
$154.50$106.18
52-Week Low
$95.16$58.75
Dividend Yield
1.37%2.51%
Enterprise Value
$202.02B

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Bank of New York Mellon Corp

BNY trades at $151.27, down 0.43% on the day, with a bullish technical signal supported by moving averages. The company has consistently beaten earnings estimates in recent quarters, with Q2 2026 results pending. Revenue growth has been steady, rising from $16.0B in 2022 to $19.8B in 2025, while net income margin improved to 29.21%. Analyst consensus is mixed with 38% buy ratings but a $156 price target suggesting modest upside. Recent news highlights strong fee income expectations and a planned 19% dividend increase.

BNY demonstrates solid fundamental strength with improving profitability and consistent earnings beats. The stock offers potential upside to analyst targets and dividend growth, but faces risks from high investing cash outflows and competitive pressures. Current valuation metrics appear reasonable relative to historical performance, though investors should monitor Q2 earnings results for confirmation of growth trajectory.

CVS Health Corp

CVS Health trades at $105.9, up 1.68% recently, with a bullish technical signal and strong analyst support (84.6% buy ratings). The company has beaten earnings estimates for three consecutive quarters, including Q1 2026 EPS of $2.57 versus $2.18 expected. Revenue growth remains robust, reaching $402.07B in 2025, though net margins are thin at 0.72%. Recent news highlights a settlement with the FTC advancing prescription drug affordability initiatives.

The outlook is positive given earnings momentum and strategic positioning in healthcare services, but risks include regulatory pressures and margin compression. The consensus price target of $110.62 suggests modest upside from current levels, supported by dividend payments and institutional confidence.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About Bank of New York Mellon Corp

BNY Mellon is a global investment company involved in managing and servicing financial assets throughout the investment lifecycle. The bank provides financial services for institutions, corporations, and individual investors and delivers investment management and investment services in 35 countries and more than 100 markets. BNY Mellon is the largest global custody bank in the world, with about $41.1 trillion in under custody and administration (as of Dec. 31, 2020), and can act as a single point of contact for clients looking to create, trade, hold, manage, service, distribute, or restructure investments. BNY Mellon's asset-management division manages about $2.2 trillion in assets.

Read more on BNY

About CVS Health Corp

Following its acquisition of Aetna in late 2018, CVS Health now provides an even more integrated healthcare-services offering for its members. Legacy CVS combined both the largest pharmacy benefit manager, processing over 2 billion adjusted claims annually, and a sizable pharmacy operation, including nearly 10,000 retail pharmacy locations primarily in the U.S. Adding a managed-care organization with 24 million medical members gives the company a strong position in the insurance industry and should help CVS better control overall healthcare costs for its clients.

Read more on CVS